02.05.2006 20:15:00

Alcon Shareholders Approve Dividend and Elect Two New Members to the Board

Alcon, Inc., (NYSE:ACL) announced the following actionswere taken by shareholders at the company's Annual General Meeting ofShareholders held today in Zug, Switzerland:

-- Approved a dividend of 1.68 Swiss francs per share to be paid on May 19, 2006 to shareholders of record on May 8, 2006 (U.S. Dollar equivalent of $1.36 per share based on exchange rates in effect today).

-- Re-elected Phil Geier to the board of directors for a one-year term of office

-- Elected two new directors to the board of directors; Paul Polman for a two-year term of office and Joe Weller for a three-year term of office.

-- Approved the cancellation of 100,000 shares, at CHF 0.20 par value per share, which have been repurchased by Alcon, Inc. and that, as a result, the share capital of Alcon, Inc. will be reduced from CHF 62,911,820.60 to CHF 62,891,820.60. Subject to fulfillment of certain formal Swiss law requirements, the cancellation is expected to become effective in July or August, 2006.

The company also announced that the board of directors re-electedCary Rayment as its chairman and elected Francisco Castaner as itsvice-chairman in a board meeting that followed the completion of theAnnual General Meeting of Shareholders.

Paul Polman replaces Dr. Wolfgang Reichenberger who resigned fromhis position as a director of the Company, effective December 31,2005. Mr. Polman began his career in 1979 with Procter & Gamble infinance and acquired a broad executive experience through assignmentsin Belgium, Holland, France, Spain, the United Kingdom and the UnitedStates. He served as Group President of Procter & Gamble's Europeanbusiness from 2001 to 2005. Mr. Polman was appointed by the board ofNestle S.A. to succeed Dr. Reichenberger as Chief Financial Officer ofNestle on January 1, 2006.

Joe Weller replaces Peter Brabeck-Letmathe, who did not stand forre-election at the Annual General Meeting on May 2, 2006. A Nestleveteran of 37 years, Mr. Weller is the former Chairman and ChiefExecutive Officer of Nestle USA. He began his career in 1968 with theCarnation Company in sales in the Memphis, Tennessee region. Headvanced within the company and was serving on Carnation's board whenNestle S.A. acquired Carnation in 1985, the same year that he waspromoted to Executive Vice President, reporting to the President andCEO. In 1989, Mr. Weller was appointed Managing Director and CEO ofNestle Australia Ltd. headquartered in Sydney. After two years, hereturned to Nestle USA in the role of President and Chief OperatingOfficer. Mr. Weller became President and Chief Executive Officer in1994, and was named Chairman of Nestle USA in 1995.

Mr. Brabeck-Letmathe has been a director of Alcon since itsinitial public offering in 2002 and has contributed greatly to Alcon'sstrategic business and financial direction over the past four years.Alcon extends its thanks and deep appreciation to Mr. Brabeck-Letmathefor his contribution to the company's success since the IPO and formany years before that while Alcon was wholly-owned by Nestle, S.A.

About Alcon

Alcon, Inc. is the world's leading eye care company with salesexceeding $4.3 billion in 2005. Alcon, which has been dedicated to theophthalmic industry for over 50 years, develops, manufactures andmarkets pharmaceuticals, surgical equipment and devices, contact lenssolutions and other vision care products that treat diseases,disorders and other conditions of the eye. For more information onAlcon, Inc., visit the company's Web site at www.alconinc.com.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Novartis AGmehr Analysen

09.01.25 Novartis Neutral Goldman Sachs Group Inc.
07.01.25 Novartis Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.01.25 Novartis Outperform Bernstein Research
17.12.24 Novartis Hold Deutsche Bank AG
10.12.24 Novartis Hold Deutsche Bank AG
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novartis AG 80,10 -0,27% Novartis AG

Indizes in diesem Artikel

NYSE US 100 16 447,86 0,76%